(Joshua Cohen/ Forbes) — While Novavax hasn’t yet sought approval by the Food and Drug Administration (FDA) for its more conventional Covid-19 vaccine, it has recently applied for licensing its vaccine in Australia, Canada, Indonesia, New Zealand, and the U.K. This hasn’t gained much traction in the U.S. media, which is odd, given that Novavax’s vaccine could not only help close the equity gap in vaccinations worldwide, but it may also help convince some who are vaccine hesitant to get vaccinated.
If Novavax does submit a marketing application in the U.S. and the FDA approves, the Novavax vaccine has the potential to boost chances of overcoming doubts on the part of the vaccine hesitant. It’s a vaccine without the baggage, if you will, of a new technology which people aren’t familiar with, and may therefore not feel comfortable receiving. (…)